

Palliative Medicine Refresher

Pennine GP Learning Group
14.11.2023

Dr Rachel Sheils, Medical Director Overgate Hospice Consultant in Palliative Medicine, Overgate and CHFT

Agenda

- Symptom control
 - Analgesia
 - Nausea and vomiting
 - Steroids
 - Breathlessness
 - Anticonvulsants
- Documentation
 - NEW community palliative MARS chart ("pink chart")
 - OOH palliative care handover form
 - ReSPECT
 - SR1 online
- Emergencies in palliative medicine
- Hot Topics
 - Substance misuse and last weeks of life
 - Day Hospice Services



Symptom control - Analgesia

- Mary 74yo
- Non-small cell lung cancer with liver metastases
- Hx COPD

Starting to get abdominal pain – generalised, not colic, not constipated

Paracetamol 1g QDS regular (wt>50kg)

What next?



Doses and titration

Co-codamol

30/500 ii QDS regular

- 240mg codeine / 24hrs
- Oral morphine equivalent = 24mg/24hrs
- No upward titration

Oral morphine solution

2-4mg PRN

- x6/24hrs max = 24mg max
- ?tests if tolerates
 (peaks/troughs → side effects/pain)

Fentanyl Patch

12 micrograms/hr

- ~ 45 mg /24 hrs oral morphine
- ~ double max Co-codamol

Buprenorphine patch

15 micrograms/hr ~26mg oral morphine/24 hrs

Slow to titrate

Morphine sulphate modified release

10mg BD

- Equivalent of 200mg codeine/24 hrs
- Scope to titrate / faster titration



Doses and titration

Co-codamol

30/500 ii QDS regular

- 240mg codeine / 24hrs
- Oral morphine equivalent = 24mg/24hrs
- No upward titration

Oral morphine solution

2-4mg PRN

- x6/24hrs max = 24mg max
- ?tests if tolerates
 (peaks/troughs→ side effects/pain)

Fentanyl Patch

12 micrograms/hr

- ~ 45 mg /24 hrs oral morphine
- ~ double max Co-codamol

Buprenorphine patch

15 micrograms/hr

~26mg oral morphine/24 hrs

Slow to titrate

Morphine sulphate modified release

10mg BD

- Equivalent of 200mg codeine/24 hrs
- Scope to titrate / faster titration



Analgesic ladders



Step 3 Moderate/severe pain

Step 2 Mild/moderate pain

Paracetamol, NSAIDs, +/adjuvants
Weak opioids (e.g. codeine,
dihydrocodeine)
Strong opioids (e.g. morphine,
oxycodone)

Paracetamol, NSAIDs, +/adjuvants **Weak opioids** (e.g. codeine, dihydrocodeine)

Step 1 Mild pain

Paracetamol, NSAIDs +/- adjuvants

WHO pain ladder



Co-codamol

30/500 ii QDS regular

- 240mg codeine / 24hrs
- Oral morphine equivalent = 24mg/24hrs
- No upward titration

3 step ladder



2 step ladder

Fentanyl Patch

12 micrograms/hr

~ 45 mg /24 hrs oral morphine

~ double max Co-codamol

Buprenorphine patch

15 micrograms/hr ~26mg oral morphine/24 hrs

Slow to titrate



Oral morphine solution

2-4mg PRN

- x6/24hrs max = 24mg max
- ?tests if tolerates
 (peaks/troughs → side effects/pain)

2 step ladder



2 step ladder

Morphine sulphate modified release

10mg BD

- Equivalent of 200mg codeine/24 hrs
- Scope to titrate / faster titration



Analgesic ladders



Step 3 Moderate/severe pain

Step 2 Mild/moderate/pain

Paracetamol, NSAIDs, +/adjuvants
Weak opioids (e.g. codeine,
dihydrocodeine)
Strong opioids (e.g. morphine,
oxycodone)

Paracetamol, NS/IDs, +/adjuvants

Weak opioids (e.g. codeine,
dihydrocodeine)

Step 1 Mild pain

Paracetamol, NSAIDs +/- adjuvants

WHO pain ladder



Use a 2-step analgesic ladder?

- Bandieri E et al 2016. Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain. Journal of clinical oncology 34:436-442
- n=240
- Primary
 Outcome:

number of patients who had a reduction of pain intensity of 20% on a numerical rating scale

| Outcome | Morphine | Weak opioid | | |
|---|----------|-------------|--|--|
| 20% reduction in pain (p<0.001, difference seen by 1/52) | 88% | 58% | | |
| 30%+ reduction in pain (p<0.001) | 83% | 47% | | |
| 50%+ reduction in pain (p<0.001) | 75% | 42% | | |
| Trial drop out due to side effects/intolerance | N=5 | N=5 | | |
| Median Edmonton Symptom Assessment System score (p<0.001) | 10 | 19 | | |



2 step ladder

Morphine sulphate modified release

10mg BD

- Equivalent of 200mg codeine/24 hrs
- Scope to titrate / faster titration



Titration, PRNs, conversions

Increasing background dose

~ 1/3-1/2 of 24-hour background

PRN

Dose conversions:

~ 1/6th of 24-hour background dose

Overgate Opioid Conversion Chart

PowerPoint Presentation (overgatehospice.org.uk)

Yorkshire and Humber Symptom Control Advice

A Guide to Symptom Management in Palliative Care

(leedspalliativecare.org.uk)

Pre-calculated opioid conversions


Opioid conversion chart 11thAug2014 (yorkhospitals.nhs.uk)





Opioid Conversion Chart

v24.11.15 RS



Always go through the centre of the chart (via oral morphine) when converting between opioids

If in any doubt, please contact the specialist palliative care team for advice:

Monday – Friday, 9am-5 pm - Calderdale Community Specialist Palliative Care Team 01422 310874 Outside these hours - Overgate Hospice 01422 379151

Symptom control – Nausea & Vomiting

- Mary 74yo
- Lung cancer with liver metastases
- Pain controlled with paracetamol 1g QDS + morphine 10mg BD

Now feeling sick and vomiting every day


What next?



Nausea & vomiting

Little RCT evidence in palliative care Extrapolated data

- Mechanistic approach
 quicker relief¹
 successful for most patients^{2,3}
- Treat any underlying cause



1 Hardy J et al (2018) BMC Cancer. 18: 510

2 Bentley A and Boyd K (2001) Palliative Medicine. 15:247-253

3 Stephenson J and Davies A (2006) Supportive Care in Cancer. 14:348-353



Raised intracranial pressure

VIIIth nucleus compression

Cough

GI irritation


Bowel obstruction

Delayed gastric emptying

Constipation

Faecal impaction

Mechanical






Central / chemical


Cerebral Cortex

 Conscious thoughts/feelings linked to limbic (emotional) system



Chemoreceptor Trigger Zone (CTZ)

Area Postrema





Chemical

DRUGS

- chemoRx
- opioids
- digoxin
- oestrogens


Altered Biochemistry

- ↑Ca²⁺
- renal failure
- ketosis

Infection

- UTI
- LRTI

Chemoreceptor Trigger Zone (CTZ)





Nausea & vomiting - Mary

Mechanical


- Cough
- Delayed gastric emptying (big liver)
- Gastric irritation (if on steroids)
- Constipation
- Brain metastases

Central / Chemical


- Anxiety
- Opioids
- Chemotherapy
- ↑Ca²⁺
- Chest infection




Mechanistic approach



Mechanistic approach



Mechanistic approach



Mechanistic approach Aprepitant Haloperidol Benzodiazepines Levomepromazine Ondansetron Cyclizine 5HT₂ 5HT₃ NK₁ M 5HT₂ **GABA** Gastrointestinal system Area postrema Vestibular system Cerebral cortex (limbic) Triggers Abdominal radiotherapy, Motion sickness, vertigo (CTZ) Fear, anxiety, Uraemia, ↑ Ca2+ chemotherapy, distension anticipatory nausea Nucleus tractus solitarius - - Cyclizine M (vomiting centre) Processing Integrates visceral sensory 5HT_o **◄ - - ≥** Levomepromazine NK₁ Autonomic motor nuclei 5HT₃ ← - Ondansetron Cerebral cortex (insula) **Endocrine** Stomach **Effector** 'Interoceptive cortex' Hypothalamus, **Emptying** Secretions Pathways 4 8 1 pituitary gland **GABA** 5HT₄ MLN SST H_2 D_2 Domperidone 'V' Erythromycin Haloperidol Octreotide Ranitidine Benzodiazepines Levomepromazine Metoclopramide Hyoscine butylbromide Nausea **↓**Appetite Vomiting Overgate &

Drugs vs Receptors

| | | | | • | | | | | |
|-----------------------------|------------------------------|------------------------------|--------------------------|--------------------------------|--------------------------------|-------------------------------|--------------------------|-----------------|-----------------|
| | D ₂ antagonist | H ₁ antagonist | Muscarinic antagonist | 5HT ₂ antagonist | 5HT ₃ antagonist | NK ₁ antagonist | 5HT ₄ agonist | CB ₁ | GABA mimetic |
| Aprepitant | - | - | - | - | - | +++ | - | - | - |
| Chlorpromazine | +++ | +++ | ++ | ++ | - | - | - | - | - |
| Cyclizine | - | ++ | ++ | - | - | - | - | - | - |
| Domperidone | ++ | - | - | - | - | - | - | - | - |
| Haloperidol | +++ | - | - | - | +, | - | - | - | - |
| Hyoscine hydrobromide | - | - | +++ | - | - | - | - | - | - |
| Levomepromazine | ++ | +++ | ++ | +++ | +, | - | - | - | - |
| Lorazepam | - | - | - | - | - | - | - | - | +++ |
| Metoclopramide | ++ | - | - | - | + | - | ++ | - | - |
| Nabilone | - | - | - | - | - | - | - | +++ | - |
| Ondansetron, granisetron | - | - | - | - | +++ | - | - | - | - |
| Olanzapine | ++ | + | ++ | ++ | + | - | - | - | - |
| Prochlorperazine | +++ | ++ | + | +/++ | - | - | - | - | - |
| Promethazine | +/++ | ++ | ++ | - | - | - | - | - | - |



Nausea & vomiting - Mary

Central / Chemical

- Opioids
- Chemotherapy

Haloperidol, levomepromazine, (cyclizine) (steroids)

• ↑Ca²⁺

Rehydration, bisphosphonates, meds as above

Chest infection

Antibiotics, meds as above

Anxiety

Anxiolytics – pregabalin, antidepressant, benzodiazepines



Nausea & vomiting - Mary

Mechanical

Cough

Treat any chest infection

Cough suppressants (e.g.gabapentin)

 Delayed gastric emptying (big liver) Steroids to reduce liver bulk? (PPI!) Prokinetic (metoclolpramide)

 Gastric irritation (e.g. if on steroids)

PPI

Constipation

Default laxatives if regular opioids

Brain metastases



Palliative Management of Bowel Obstruction

reduce any narrowing

of the gut

- extrinsic compression (steroids)

- gut wall inflammation (steroids, ondansetron)

reduce gut secretions

- hyoscine, octreotide

increase gastric emptying

- metoclopramide

or

<u>reduce motility (if colic)</u>

- cyclizine, hyoscine

reduce nausea

- cyclizine, metoclopramide, levomepromazine, ondansetron

Get bowels going if you can

-docusate



Special circumstances

Parkinson's disease

- Avoid dopamine blockade
- Haloperidol *
- Metoclopramide *
- Prochlorperazine *

✓ Worth considering

- domperidone (DA blockade but doesn't cross BBB) oral only ✓
- levomepromazine low dose despite DA activity (case series) –
 sedating ✓
- Ondansetron constipating ✓



Special circumstances

CYCLIZINE


- Anti-muscarinic
- Anti-histaminergic
- Risk = constipation

METOCLOPRAMIDE

- Prokinetic
- DA block, 5HT4 agonist
- Risk = colic

PROKINETIC EFFECT BLOCKED

Potential toxicity of both with limited benefit





PPIs

- Side effects
 - Diarrhoea
 - Low sodium
- Try famotidine?

- Can't take/tolerate/absorb oral or orodispersible
 - Can use syringe driver of esomeprazole
 - 40mg over 24 hrs CSCI
 - NOT on red list



Symptom control – steroids

- Mary 74yo
- Lung cancer with liver metastases
- Pain controlled with paracetamol 1g QDS + morphine 10mg BD
- Now feeling sick and vomiting every day
- ? Liver metastases and delayed gastric emptying (other causes of N&V possible!)

Going to try some steroids to reduce liver capsule pain, reduce gastric emptying delay by reducing extrinsic pressure on gastric outlet from liver mets, ??central cause of N&V (brain mets).

- What dose?
- Will it work?
- What are the risks?



Symptom control – steroids

Hardy et al. Practice review: Evidence-based quality use of corticosteroids in the palliative care of patients with advanced cancer.

Palliative Medicine ISSN (Print): 0269-2163 - ISSN (Online): 1477-030X



Literature search

| P | Population | Pts with advanced cancer PLUS other problems |
|---|--------------|--|
| I | Intervention | Use of systemic corticosteroids various doses – see specific reviews |
| С | Comparison | No steroids/steroids at other doses |
| 0 | Outcome | Relief of symptoms/QoL/ functional status – see specific reviews |



Strong evidence:

DO

- use for Sx of raised ICP (4mg as effective as 16mg wrt performance status at 4 weeks)
- use shortest course/lowest effective dose
- educate patients properly
- use 1-2 doses/day (not TDS/QDS)
- monitor capillary blood glucose when first starting steroids
- remember hyperglycaemia is common and of rapid onset
- long term steroids require regular review of Side Effects

DON'T

stop abruptly if taking >4mg dex/day
 for >5days



Moderate evidence

DO

- use for MSCC (not clear what dose is needed)
- monitor for oral thrush
- document reason for prescribing steroids
- monitor for efficacy and SE in long term use
- take a full medicines history
- keep to <2 weeks if no benefit

DON'T

 Prescribe more than 12mg dex/day if Hx of neuropsychiatric illness



Tentative evidence:

DO

- Use to speed resolution of bowel obstruction
- Use to treat SOB in **lymphangitis carcinomatosis**
- Use to prevent symptoms and complications of SVCO
- Use to treat **appetite**
- Use to treat pain
- Use PPI or H2 antagonist if steroids for >2/52
- <u>avoid</u> prior to diagnosis of a mass lesion that might be lymphoma unless vital

DON'T

 Px steroids without risk assessment (skin integrity/wound healing, GI risk, infection...)



Inadequate evidence for recommendation re:

- N&V in liver metastases
- oedema from obstructive lymphadenopathy
- bronchorrhoea
- N&V other than due to chemorx
- fatigue
- SOB
- cough from cancer
- QoL
- outcome in terminal care
- whether bursts reduce toxicity or have different efficacy

- reversibility of side effects on stopping Rx
- whether Ca Vit D helps
- whether prophylactic antifungals or Ab+ help
- which is the steroid of choice
- starting dose irrespective of condition
- optimal weaning esp for different conditions and people
- whether to continue when dying
- what the optimal Rx of steroid induced hyperglycaemia

 Overgate

 HOSPICE

Symptom control – Dyspnoea

- Mary 74yo
- COPD, Lung cancer with liver metastases
- Pain controlled with paracetamol 1g QDS + morphine 10mg BD
- N&V controlled with haloperidol 1.5mg nocte & docusate 100mg nocte

Increasingly breathless

- What might be reversible/modifiable?
- Palliation



Treatable cause for SOB....?

- Infective exacerbation COPD
- PE
- Effusion
- Anaemia
- Anxiety

Treat the treatable if prognosis sufficient, and benefits outweigh burdens.



Palliation of SOB

Non- pharmacological

Drugs

- Fans
- Rectangle breathing
- Relaxation
- Mantra
 - Lots of oxygen in my blood
 - NOT my last breath *****

- Opioids
- Benzodiazepines only if anxiety
- Rx of depression & anxiety
- ?? oxygen

FANS

- -Schwartzstein R, Lahive K, Pope A et al. Cold facial stimulation reduces breathlessness induced in normal subjects. Am Rev Resp Disease 1987;136(1):58-61.
- -Liss H, Grant B. The effect of nasal flow on breathlessness in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1988;137(6):1285-8.
- -Simon P, Basner R, Weinberger S et al. Oral mucosal stimulation modulates intensity of breathlessness induced in normal subjects. Am J Respir Crit Care Med 1991;144(2):419-422.
- -Galbraith S, Fagan P, Perkins P et al. Does the use of a handheld fan improve chronic dyspnoea? A randomised, controlled, crossover trial. J Pain Sy Manage 2010;39(5):831-838.



Safety of Medication for chronic breathlessness

concern = respiratory depression

Ekstrom

COPD with LTOT – 4 year follow up No increase in mortality or hospitalisation on **30mg/day or less**

Bajwah

ILD

No increase in mortality or hospital admission with doses **30mg/day or less**

| Ekstrom 2014- BMJ | ≤30mg morphine / 24 hrs | No Δ mortality |
|-------------------------|----------------------------|---------------------|
| | >30mg morphine / 24 hrs | Increased mortality |
| Benzodiazepines (any) | | Increased mortality |

Trials

- one case of harm with COPD and transmucosal fentanyl
 - NB pt misused the fentanyl in that he took 10x the recommended no. of doses /day
- one case of harm with nebulised opioid on top of MR opioid
- one case of harm in COPD where pt had MR opioid and then a large dose of IR opioid



Opioids – efficacy for dyspnoea

Opioids for Breathlessness: a narrative review

Johnson & Currow BMJSPC 2020; 10:287-295

SOB experienced via CNS "threat centres" – rich in opioid receptors SOB reduced by endogenous opioids

Role of frontal cortex

- Activated in chronic SOB vs healthy volunteers
- Anxiety and depression increase activation
- Pulmonary rehabilitation reduces activation

Most evidence is:

- for morphine
- in patients with COPD

Most trials are:

- Randomised
- placebo-controlled
- Double blinded
- Very long-acting opioid

2014 meta analysis

- benefit from steady state is more than from single doses
- Moderate evidence of efficacy and safety

2016 Systematic review

 moderate evidence of reduced SOB



Opioids & Dyspnoea

Background SOB

- Trial of low dose MR morphine for 1 week, starting at 10mg/24 hrs (\(\gamma\) to 20mg then 30mg if no response)
- 2/3rd had benefit
- Of those 70% at 10mg/day, 20% at 20mg/day, 8% at 30mg/day
- Biggest benefit was in the first 24 hrs, but benefit continued to ↑ for 6 days with no dose ↑

→ SLOW TITRATION

Pre exertion PRN

- morphine immediate release
- Increased endurance, reduced SOB



Dyspnoea

The benefit of opioids is blocked by anxiety and depression

→ ?Anxiolytic antidepressants, pregabalin for anxiety

Oxygen

No symptomatic benefit over a fan unless significant hypoxia Psychological tethering

Caution in CO₂ retention – can look like over-opiation (Flap instead of jerks, reduced respiratory rate, drowsiness)



Symptom control – Seizures

- Mary 74yo
- COPD, Lung cancer with liver metastases
- Pain controlled with paracetamol 1g QDS + morphine 10mg BD
- N&V controlled with haloperidol 1.5mg nocte & docusate 5ml nocte
- Low mood, anxious, pleural effusions (not for draining) using hand-held fan, mirtazapine – breathlessness improving

- New episodes of right arm twitching over last few days
- Headache
- Generally deteriorated prognosis? weeks
- What next?



Seizures - no previous anticonvulsant

- Brain Scan? (what will it change?)
- Steroids? (maybe if pressure symptoms/have time to titrate anticonvulsants)

Is the prognosis very short (≤ few weeks)?

NO

- After 1st seizure

 (don't wait for 2nd)
- Start:
 - levetiracetam 500mg BD (can increase by 250-500mg BD each 2 weeks)
 - valproate 150/200mg MR BD (can increase by 150-200mg every 3 days)

YES

- Start midazolam syringe driver 20-30mg/24 hrs
- PRN
 - midazolam 10mg SC or buccal (10mg/ml so small volume but expensive)
 - ?lorazepam 0.5-1mg PRN
 - (Diazepam rectal solution)



Seizures - already on anticonvulsants

- Continue to titrate anticonvulsant if needed
- ? Steroid cover while titrating up if due to (suspected) brain metastases
- ? Midazolam cover while titrating up

Might lose swallow?

→ have S/C meds ready

BACKGROUND

- Convert valproate or levetiracetam to syringe driver
- Max VOLUME in 1 SD = 22ml
 - Valproate = 2200mg/24hrs
 - Levetiracetam = 2200mg/24 hrs

PRN

- midazolam 10mg SC or buccal (10mg/ml so small volume but expensive)
- ?lorazepam 0.5-1mg PRN
- (Diazepam rectal solution)



Seizures - bits a pieces

PRNs

Give if fitting ≥ 5 minutes

Midazolam 10mg PRN
Total 80mg maxin 24 hrs (SD + PRN)

After midazolam max

- Use phenobarbital
- Start 100-200mg IM hourly max
- Once seizures settle, put cumulative dose in SD over 24 hrs
- Continue to give PRN if needed

- Gabapentin /pregabalin
 Abrupt withdrawal (e.g.
 loss of oral route when
 dying) can cause seizure
 (even if no Hx of seizures)
 →replace with
 midazolam in
 syringe driver
- Midazolam may replace some of neuropathic analgesic effect



Anticipatory medications Parkinson's disease – dying/can't swallow

- Reduced movement/ facial expression
- Risk of poor control of other symptoms
- Stiffness, reduced movement, pressure areas, friction from tremor

ACTIONS

- Try to "unlock"
- Co-beneldopa
 - Buccal/crushed
- Replace background with ROTIGOTINE PATCH
- (optimal calculator)



Calculator for patients who cannot have an NG tube or with GI failure


Select your patient's usual medication, dosage and frequency from the drop down menus below. After each selection click "Add Drug".

When you have entered all of the Parkinson's medication in their regime, click "Calculate" to see what to convert it to.

Click "Reset" to clear all selections.

| Drug: | Dosage:Frequency: | | | |
|----------------------|-------------------|-------------------|-----------|--|
| | v | | | |
| Reset | Add Drug | ld Drug Calculate | | |
| Patient's Usual Drug | | Dosage | Frequency | |





Results

Convert to: Rotigotine Patch 12mg/24hrs.

If the patient has Dementia or Delirium we advise Rotigotine 8mg/24hrs.

Please note, maximum dose of Rotigotine is 16mg in 24 hours. Do not cut patches to achieve required dose.



Requests for GP support from SPCT

&

Documentation



Who should you refer to SPCT?

The SPICT™ -**SPICT**



Supportive and Palliative Care Indicators Tool (SPICT™)



The SPICT™ is used to help identify people whose health is deteriorating. Assess them for unmet supportive and palliative care needs. Plan care.

Look for any general indicators of poor or deteriorating health.

- Unplanned hospital admission(s).
- · Performance status is poor or deteriorating, with limited reversibility (eg. The person stays in bed or in a chair for more than half the day.)
- Depends on others for care due to increasing physical and/or mental health problems. The person's carer needs more help and support
- Progressive weight loss; remains underweight; low muscle mass.
- · Persistent symptoms despite optimal treatment of underlying condition(s).
- The person (or family) asks for palliative care; chooses to reduce, stop or not have treatment; or wishes to focus on quality of life.

Look for clinical indicators of one or multiple life-limiting conditions.

Functional ability deteriorating due to progressive cancer.

Too frail for cancer treatment or treatment is for symptom control.

without help.

Eating and drinking less; difficulty with swallowing. Urinary and faecal incontinence.

Not able to communicate by speaking: little social interaction.

Frequent falls; fractured femur. Recurrent febrile episodes or infections; aspiration pneumonia.

Neurological disease

ive deterioration in physical and/or cognitive function despite optimal therapy.

Speech problems with increasing difficulty communicating and/or progressive difficulty with swallowing.

Recurrent aspiration pneumonia:

Persistent paralysis after stroke and ongoing disability.

Heart/ vascular disease

Heart failure or extensive, untreatable coronary artery disease; with breathlessness or chest pain at rest or on minimal

Severe, inoperable peripheral vascular disease.

Respiratory disease

Severe, chronic lung disease; or on minimal effort between exacerbations

Persistent hypoxia needing long term oxygen therapy.

respiratory failure or ventilation is

Deteriorating with other conditions, multiple conditions and/or complications that are not reversible; best available treatment has a poor outcome.

Stage 4 or 5 chronic kidney

Kidney failure complicating

Cirrhosis with one or more

diuretic resistant ascites

hepatic encephalopathy

recurrent variceal bleeds

bacterial peritonitis

Liver transplant is not possible.

treatments.

Liver disease

other life limiting conditions or

ase (eGFR < 30ml/min) with

- Review current treatment and medication to make sure the person receives optimal care; minimise polypharmacy.
- · Consider referral for specialist assessment if symptoms or problems are complex and difficult to manage.
- Agree a current and future care plan with the person and their family/people close to them. Support carers.
- Plan ahead early if loss of decision-making capacity is likely.
- Record, share, and review care plans.

Proactive Identification Guidance v7 (2022).pdf (goldstandardsframework.org.uk)

framework

Proactive Identification Guidance - identifying patients' decline earlier, enabling more proactive care

or PIG (previously known as the GSF Prognostic Indicator Guidance), aims to enable the earlier identification of people who may need

additional supportive care as they near the end of their life (see GMC and NICE definition of end of life care), to include final year of life as

well as final days. This includes people with any condition, in any setting, given by any care provider (not just those needing specialist

palliative care), following any trajectory of decline for expected deaths (see below). Additional contributing factors when considering

prediction of likely needs include underlying co-morbidities, current

Three Trajectories of Illness

Why is it important to identify patients early? Earlier identification of people who may be in their final stage of life

leads to more proactive person-centred care as recommended in the NHSE Long term Plan (2019) and NICE guidance (2021). Earlier recognition of decline leads to earlier anticipation of likely needs, better planning, fewer crisis hospital admissions and care tailored to

peoples' wishes, with better outcomes enabling more people to live

GSF cross boundary care sites

and die where they choose. Once identified, people are included on a register and where available the locality/electronic register, triggering specific active supportive care, as used in all GSF programmes and in

The 3 key steps of GSF - Early

proactive identification of patients is the crucial first step of GSF, used by

many thousands of doctors and nurses

For more information on GSF, how it is

used in practice to help identify

patients early, assess needs and wishes

through advance care planning

discussions and plan care tailored to

in the community and hospitals.

The Gold Standards Framework **Proactive Identification Guidance (PIG)**

GSF PIG 7th Edition June 2022 Keri Thomas, Max Watson (HUK), Julie Armstrong Wilson and the GSF team

The National GSF Centre's guidance for clinicians to support earlier identification of patients nearing the end of life, leading to improved

- desince care planning and DNAPP discussion as early as possible. IT 28 General inchesions of section and increasing sections are sensitively as a comparability of the properties of the support Repeated unplanned hospital admissions or acute crises at home Advanced disease, unstable, deteriorating complex symptom burder Prisence of significant multi-morbidities. Decreasing existly—functional performance status declining (e.g., Barthel or standsky Performance score, Bookwood) minted self-care. Barthel or standsky Performance score, Bookwood) minted self-care declining (e.g., Garthel or standsky Performance score, Bookwood) minted self-care.

heart disease/arrythmias multi-morbidities including diabetes, obesity depression, hyponatraemia, high BP, declining renal function, anaemia

Considered eligible for DS1500 payment

Existing conditions if they are at risk of dying from a sudden acute crisis in their condition

. Life threatening acute conditions caused by sudden spending more than 50% of time in bed/lying down, prognosis estimated in months catastrophic events.'
NICE Guidance in End of life care 2021 Identification

tement 1 Adults who are likely to be approaching the end of their life are identified using locally developed systems.'
NICE Service Delivery 2019 https://www.nice.org.uk/guida Services should develop systems to identify adults who are likely to be approaching the end of their life e.g., using tools such as GSF proactive identification guidance (PIG).

Definition of End of Life Care General Medical Council

or days) and those with: Advanced, progressive, incurable conditions

for-doctors/treatment-and-care-towards-the-end-of-life
NHS - https://www.nhs.uk/conditions/end-of-life-care/what-it-

<u>involves-and-when-it-starts/</u>
The GMC definition of End of Life Care, used by the NHS, NICE

and others is 'People are 'approaching the end of life' when they are **likely to die within the next 12 months**. This includes

people whose death is imminent (expected within a few hours

· General frailty and co-existing conditions that mean they

are expected to die within 12 months.

SARS COVID 19 infections can cause rapid decline, emphasising the importance of early advance care planning and screening Contributing factors include age, multi-morbidity, BAME and ocial status, etc. Pulse oximetry SpO2 of 92% or under trigge nmediate treatment - more information see NHS guidance or



For information on the development of the GSF PIG, its use in practice, evidence base, applications and when referencing it, please refer to

onditions, would you be surprised if the patient were to die in the

- chronic liver disease and cirrhosis mortality See CTP calculato

FRAILTY, DEMENTIA and MULTI-MORBIDITIES

- need to stay at home, needs regular help, uses stick/walker

- frailty. Triggers to consider that indicate that someone is entering a
- Completely dependent on others for care or unable to do ADL Recurrent episodes of delirium
- Urinary and faecal incontinence, and Barthel score <3
- Plus: Weight loss, urinary tract Infection, skin failure or stage 3 or 4 pressures ulcers, recurrent fever, reduced oral intake
- Increasingly relevant in ageing population needing complex care
 2 or more long term conditions including physical, mental, learning disability, fraity, sensory impairment, alcohol misuse

 Consider multi-morbidity approach if have fraity, physical + mental
- conditions, not managing ADL or treatments, using multiple services frequent falls or crisis admissions

The GSF Proactive Identification Guidance (PIG) June 2022 vs7 © The Gold Standards Framework Centre in End of Life Care



Urgent request for support from specialist palliative care CNS

"Face-to-face" review
- often re MCCD
(so includes video link during life)

Attended during last illness

- Access to records/results
- Must see in 28 days before death **OR** after death

Occasionally – no GP attended during last illness

- Must be seen in 28 days before death, or referred to coroner
- (e.g. self referral to A&E with symptoms, diagnosed with widely metastatic ca, wants to die at home, Fast Track discharge, dies soon after return home)

Request for physical examination

- Decisions about reversible treatments - ? Ascites for drainage or constipation?
- Chest infection warranting treatment or other cause of breathlessness.

Request to write/amend pink chart



Pink form = anticipatory + SD

Recognition that forms could change to reduce risk of errors

- E.g. on discharge from hospital
- Nurse brings pink chart.
- Family comes to collect pink chart when done.
- If nurse finds an error → repeat

Chart revised to reduce errors

Pre-populated:

- Indications
- Frequency
- Maxmimum dose except for opioids

OPIOIDS

maximum dose =

syringe driver + 6 PRNs



Pink form - Syringe driver

COMMUNITY PALLIATIVE CARE CHART





| Allergies and Adverse Drug Substances & the nature of t | | | |
|---|------------|---------------|------|
| It is mandatory to complete | this secti | o n | |
| Medicine/Substance Reaction | | | |
| Sign Date | | | Date |
| Print Name G | | MC/NMC number | |
| Allergy status unconfirmed. Authority to administer ceases after 24 hours | Sign (NA | ME) GMC/NMC | Date |

| First Name | Surname |
|------------|--|
| Address: | |
| NHS No: | DOB: |
| | ministration of a stat dose g a new syringe <u>driver</u> |

SC SYRINGE DRIVER OVER 24 HOURS

| Syringe driver | | Dose | *Dose t | itration (community use) |
|----------------|------------------------------|------|---------|--------------------------|
| Drug (1) | | | | |
| Drug (2) | | | | |
| Drug (3) | | | | |
| | | | | |
| Diluent: | | | | |
| Prescriber sig | Prescriber name (print) Date | | Date | |

Maximum volume 22ml

(23ml if line primed)



'WHEN REQUIRED' DRUGS

Please remember to issue a prescription of Water for injection to allow these drugs to be administered

| ROUTE | Prescriber sig (Print name) Date | | Date |
|---|--|--|--|
| SC | | | |
| | Frequency | One hourly | |
| Max dose in 24 | Max dose in 24 hours including syringe driver content: | | |
| | | | |
| ROUTE | ROUTE Prescriber sig (Print name) | | Date |
| al) SC | | | |
| g | Frequency | One hourly | |
| Indications Anxiety, dyspnoea, agitation, restlessness Max dose in 24 hours | | | 4 hours – 80mg |
| Indications 10mg to be given for seizure or major haemorrhage | | | |
| | ROUTE al) SC g onoea, agitation, restlessn | ROUTE Prescriber signal) SC Frequency Frequency approach agitation, restlessness | Frequency One hourly Max dose in 24 hours including syringe driver content ROUTE Prescriber sig (Print name) al) SC g Frequency One hourly Onoea, agitation, restlessness Max dose in 24 |

| Drug ROUTE | | Prescriber sig(Print name) | | Date | |
|-----------------------------------|------|----------------------------|------------------|------------------|---------------|
| HYOSCINE BUTYLBROMIDE : | | SC | | | |
| Dose | 20mg | | Frequency | One hourly | |
| Indication Respiratory secretions | | | Max dose in 24 l | nours - 120mg | |
| Indication Colic | | | | Max dose in 24 l | nours - 300mg |

| Drug | Drug ROUTE | | Prescriber sig_(Print name) | | Date |
|---|------------|-----------|-----------------------------|-------------|------|
| HALOPERIDO | L | SC | | | |
| Dose 0.5-3mg | | Frequency | Two hourly | | |
| Indications Nausea, Agitation, Hallucinations | | | Max dose in 241 | nours - 5mg | |

| Drug | ROUTE | | Prescriber sig (Print name) | | Date |
|-------------|-------|----|-----------------------------|-----------------|---------|
| | | SC | | | |
| Dose | | | Frequency | | |
| Indications | | | | Max dose in 241 | nours – |

Pink form = anticipatory + SD



Pink form = anticipatory + SD

PRN opioids

1/6th of 24hr background dose

Opioid naïve

lower dose if frail, thin, elderly, sensitive to side effects

Oxycodone 1-2mg SC PRN

eGFR <40

↓

morphine
accumulates

↓

use
oxycodone



Pink form = anticipatory + SD

PRN opioids

1/6th of 24hr background dose

Opioid naïve

lower dose if frail, thin, elderly, sensitive to side effects

Oxycodone 1-2mg SC PRN

eGFR <40

↓

morphine
accumulates

↓

use
oxycodone




Anticipatory Meds

- SYSTMONE anticipatory meds prescribing
- Only for Morphine 10mg/ml Injection
- "personal administration" NEEDS TO BE MANUALLY UNTICKED
- otherwise prescription does not get electronically transferred to pharmacy
- automatically unticked on the other strengths
- needs to be changed at ICB level has been requested.



Anticipatory Meds



Pink form = anticipatory + SD


- Mary may soon start to die
- Might soon not be able to swallow.....
- Needs PRN
 - Morphine
 - Midazolam
 - Hyoscine butylbromide
 - Haloperidol

5 ampoules of each

- Ampoules of water / saline
- If on levetiracetam (or valproate)
 - ensure enough SC to start a syringe driver
- If on steroids to control seizures
 - ensure daily SC dose



ReSPECT



- Not just for palliative care patients
- Significant illness => complete before it gets to palliative phase
- Respect Epaccs use high priority alert and tick box on EPaccs
- Will replace DNA CPR



OOH handover form

| P | ALLIATIVE CARE | HANDOVER FORM |
|--|--|---|
| ' | (Please send elect | tronically if possible) |
| PATIENT DETAILS Name: Address: | NHS Number: DOB: | CARER DETAILS Name: Relationship: Address: |
| Postcode: Telephone/Mobile: FORM COMPLETED BY: | | Telephone/Mobile: |
| Name (print): | | Signature: |
| Designation: | | Date: |
| tests in particular renal funct | ion/EGFR to aid opioid pres | cribing. |
| FUTURE PLANNING Preferred place of care | Home Care home Hospice Hospital | DNACPR decision Is there a form in the patient's house? Yes □ No □ |
| WHICH ANTICIPATORY DR | UGS ARE AVAILABLE IN 1 | |
| Opioid: | | Anti-secretory drugs: |
| Antiemetic: | | Sedative: |
| other advance care plan, A | CP, in the house?) | patient not want further hospital admission, or is any . for Kirklees residents contact District Nurses on |
| 0300 304 5555 or Kirkwoo on 07917 106263 or Overg | d Hospice on 01484 5579 ate Hospice on 01422 37 | 10. For Calderdale residents, contact District Nurses |
| to Local Care Direc | t on patientforms.LCD@ | E PATIENT'S GP VIA SECURE NHS.NET EMAIL and @nhs.net NSFRT 'URGENT PALLIATIVE CARE HANDOVER'. |

A PAPER VERSION OF THIS FORM MUST STAY IN THE PATIENT'S HOME.

CHFT Specialist Palliative Care Team September 2019

Review September 2021

- Scan -> secure email to NHS111
- Patientforms.LCD@nhs.net
- LCD practitioner gets flag when opening S1 and EMIS
- If completed by SPCT there will be a high priority reminder on S1 Home Page



SR1 (formerly known as DS1500)

https://portal.national.ncrs.nhs.uk

Important

Find out about the <u>changes to the Special Rules</u> <u>process (opens in a new tab)</u> in the benefit system.

Send an SR1 form

The SR1 form has replaced the DS1500 form. You can use it to support a benefit claim for a patient of any age made under the Special Rules.

Use this service to tell the Department of Work and Pensions (DWP) that you have a patient who:

- · has a progressive disease and
- you would not be surprised if they were to live for less than 12 months

Start now >

Same info as on paper

Option to save a copy of the submitted form – I tend to upload to S1.



PROGNOSIS Too short to benefit from treatment?

Declines intervention despite knowing worst outcomes?

QoL likely to be adversely affected by treatment of underlying process rather than palliative of symptom?

SPCT +/- hospice

Emergencies



Reversible condition?

Prognosis > weeks

Or if shorter prognosis – symptom won't be adequately managed with palliative medication

Patient agrees to acute care

Emergencies

ACUTE ONCOLOGY

number

Mon-FRI 9-5

Via Switchboard 01422 222999



Emergencies

Malignant spinal cord compression

NICE – don't wait for development of neurological signs Crescendo pain in known / suspected cancer Especially radicular pain

High index of suspicion for MSCC

Dexamethasone 16mg stat
PPI
Urgent MRI whole spine via acute oncology



Emergencies

- Febrile neutropenia
- Acute oncology
- Blood cultures then IV Ab+ within the golden hour



Emergencies

- **SVCO**
- Steroids
- PPI
- Acute oncology ? XRT ? Stent



Substance misuse, last days of life

- Sublingual buprenorphine complicated to convert to SC medication when cannot manage SC
- Recovery steps extremely helpful in advising on dose/formulation adjustments even if patient not known to them
- General recommendation for switch from buprenorphine to methadone in weeks leading up to death.... Easy to convert to Syringe driver when oral route lost.... Divide by

Hospice services

- Hubs one for each PCN + Todmorden
- Time to Think dementia pt and carer
- Support and Wellbeing pt only
- Bereavement groups access if patient know to Overgate



SPCT CNS team − 01422 310874

7 days /week



CHFT Motor Neurone Disease Care Co-Ordinator

Beth Macdonald <u>Elizabeth.Macdonald2@cht.nhs.uk</u>

- Is a qualified OT (not a nurse) other job is working as OT for Locala in Huddersfield
- Works Tuesdays, Thursdays, Fridays
- Covers patients in Calderdale and Huddersfield
- Co-ordinates care, and works with Rachel Sheils in MND clinic - aim for 2 clinics/month – mix of in person at Acre Mill (Hudds) and online to improve accessibility

Yorkshire and Humber Symptom control guidance to follow shortly...

Will be a webpage rather than an app or booklet.



Summary

Symptoms

- Treat underlying causes
- Pain
 - Low dose morphine
 - Conversion guidelines
- N&V
 - Mechanistic approach
- Steroids
 - Evidence is sparse for most things
- Breathlessness
 - Start low/go slow
 - Morphine 30mg/24 hrs max
 - Treat anxiety & depression
 - PRN for SOB ¼ of usual PRN opioid
- Seizures
 - SD levetiracetam/valproate
 - Midazolam otherwise
 - Phenobarbital if still not resolved

Emergencies

Reversible or palliative Rx ?

Documentation

- Pink chart
- OOH handover form
- ReSPECT
- SR1

Hot Topics

- Substance misuse –Recovery steps
- DH services

